Sage Journals: Discover world-class research

Abstract

The Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA) are the most commonly used tools for the evaluation of psoriasis disease severity in clinical trials. Based on U.S. Food and Drug Administration requirements, many recent trials concerning measurement of psoriasis disease severity have included the PGA as a primary endpoint alongside the PASI. In this commentary, we review the advantages and disadvantages of the PASI and PGA scales, and discuss an example of a psoriasis patient in whom PGA fails to capture clinically significant disease improvement. We argue that despite its limitations, the PASI is a more accurate and descriptive instrument than the PGA for the assessment of psoriasis severity.

Keywords

psoriasis clinical trials treatment outcome psoriasis area and severity index physician global assessment

Get full access to this article

View all access options for this article.

References

Spuls

P.I.

Lecluse

L.L.

Poulsen

M.L.

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.

J Invest Dermatol. 2010 Apr; 130(4): 933–43.

Dermatologic and Ophthalmic Drugs Advisory Committee 49th Meeting 1998: Food and Drug Administration DoHaHS, Public Health Service, March 20, 1998. Washington, DC: Miller Reporting Company, Inc; 1998.

Fredriksson

Pettersson

. Severe psoriasis — oral therapy with a new retinoid. Dermatologica. 1978; 157(4): 238–244.

Puzenat

Bronsard

Prey

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature.

J Eur Acad Dermatol Venereol. 2010 Apr; 24 Suppl 2: 10–6.

Gourraud

P.A.

Le Gall

Puzenat

Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis.

J Invest Dermatol. 2012 Sep; 132(9): 2171–5.

Fleischer

A.B.

Jr. Rapp

S.R.

Reboussin

D.M.

Vanarthos

J.C.

Feldman

S.R.

. Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol. 1994 Jun; 102(6): 967–9.

Marks

Barton

S.P.

Shuttleworth

Finlay

A.Y.

. Assessment of disease progress in psoriasis. Arch Dermatol. 1989 Feb; 125(2): 235–40.

Langley

R.G.

Ellis

C.N.

. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004 Oct; 51(4): 563–9.

Offen

Chuang-Stein

Dmitrienko

Multiple co-primary endpoints: medical and statistical solutions. A report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America.

Drug Inf J. 2007; 41: 31–46.

10.

Buzney

E.A.

Kimball

A.B.

. A critical assessment of composite and coprimary endpoints: a complex problem. J Am Acad Dermatol. 2008 Nov; 59(5): 890–6.

11.

Callis Duffin

Gottlieb

A.B.

. Outcome measures for psoriasis severity: a report from the GRAPPA 2012 annual meeting. J Rheumatol. 2013 Aug; 40(8): 1423–4.

Article Commentary: Clinical Severity Measures for Psoriasis: A Case for the PASI

Abstract

Keywords

Get full access to this article

References